The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review

被引：0
|
作者：
Jonathan Adachi
Niall Lynch
Hans Middelhoven
Manjit Hunjan
Warren Cowell
机构：
[1] McMaster University,Health Outcomes Research
[2] Global Health Outcomes,Healthcare Management
[3] Economic Value Strategy,undefined
[4] GlaxoSmithKline UK Ltd,undefined
[5] Roche Products Limited,undefined
来源：
BMC Musculoskeletal Disorders | / 8卷
关键词：
Vertebral Fracture; Fracture Risk; Alendronate; Osteoporotic Fracture; Risedronate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] ASSOCIATION BETWEEN BISPHOSPHONATE USE AND THE RISK OF STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Huang, H. -K.
    Lin, S. -M.
    Lin, J. -Y.
    Peng, C. C. -H.
    Tu, Y. -K.
    Loh, C. -H.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S339 - S340
  • [32] Persistence with bisphosphonate therapy in older people
    Melo, M
    Qiu, F
    Sykora, K
    Juurlink, D
    Laupacis, A
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (06) : 1015 - 1016
  • [33] The Association between Long-Term Bisphosphonate Use and the Risk of Fracture among Females with Osteoporosis in Taiwan
    Wu, Chung-Hsuen
    Wang, Chi-Chuan
    Lu, Hsien-Tsung
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 98 - 98
  • [34] The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy
    Lo, Joan C.
    Hui, Rita L.
    Grimsrud, Christopher D.
    Chandra, Malini
    Neugebauer, Romain S.
    Gonzalez, Joel R.
    Budayr, Amer
    Lau, Gene
    Ettinger, Bruce
    BONE, 2016, 85 : 142 - 147
  • [35] FDA reviews data regarding association between oral bisphosphonate therapy and esophageal cancer risk
    不详
    FORMULARY, 2011, 46 (09) : 373 - 373
  • [36] Better adherence to bisphosphonate therapy is associated with reduced nonvertebral fracture risk
    Sunyecz, John A.
    Bachmann, Gloria
    Barr, Charles E.
    Silverman, Stuart
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 25S - 25S
  • [37] Bone: Bisphosphonate therapy after cardiac transplant reduces fracture risk
    Wilson C.
    Nature Reviews Endocrinology, 2009, 5 (7) : 356 - 356
  • [38] Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study
    Andréa Senay
    Julio C. Fernandes
    Josée Delisle
    Suzanne N. Morin
    Sylvie Perreault
    Archives of Osteoporosis, 2019, 14
  • [39] Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study
    Senay, Andrea
    Fernandes, Julio C.
    Delisle, Josee
    Morin, Suzanne N.
    Perreault, Sylvie
    ARCHIVES OF OSTEOPOROSIS, 2019, 14 (01)
  • [40] Persistence of weekly oral bisphosphonate therapy: Wasted drug and fracture costs due to early discontinuation
    Sheehy, Odile
    Kindundu, Christian
    Barbeau, Martin
    LeLorier, Jacques
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S78 - S79
12345